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Available online 30 March 2015AbstractCyanobacteria are emerging as an important source of novel bioactive secondary metabolites. Recently, it has also been reported as a rich
source of bioactive molecules such as apratoxins, lynbyabellin, and curacin A. Some compounds have exhibited very interesting results and
successfully reached Phase II and Phase III clinical trials. Furthermore, cyanobacterial compounds hold a bright and promising future in sci-
entific research and provide a great opportunity for new drug discovery. In 2005, a number of new technologies have led to the development of
new miniaturized screens based on cell cultures, enzyme activities, and ligand receptor binding. The use of a computational method based on
targeted metabolite data has provided additional insight into the ligand-based approach that employs conformational analysis of known ligands.
This approach has implications for developing novel compounds for structure-based drug design. Hence, this review article mainly focuses on
baseline information for promoting the use of cyanobacterial bioactive compounds as drugs for various dreadful human diseases, using the
computational approach.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Natural products are an important source of new structures
leading to drugs in all major disease areas. This issue illus-
trates current activities and trends in the research of natural
products and drug discovery. Medicinal chemistry is the
cornerstone for successful hit-to-lead exploration and further
lead optimization. An increase in productivity in the drug
discovery process has been achieved with the implementation
of library chemistry and high throughput screening. Despite
these efforts, the number of new chemical entities reaching the
market has not increased. Only one drug originated from a de
novo combinatorial chemistry approach. However, natural
products remain an important source of structures contributing
mostly to semisynthetic or synthetic drugs in all disease areas.* Corresponding author. PG and Research Department of Botany and
Microbiology, A.V.V.M. Sri Pushpam College (Autonomous), Poondi 613 503,
Thanjavur District, Tamil Nadu, India.
E-mail address: svijaya_kumar2579@rediff.com (S. Vijayakumar).
http://dx.doi.org/10.1016/j.jacme.2015.02.004
2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. PublishedTherefore, therapeutic effects of natural product-derived drugs
are predominantly achieved in antibiotic therapies, oncology,
and immunoregulation.1 It is less likely to identify potent
natural products against molecular targets of human diseases.
Natural products are important sources of new structures,
leading to drugs in all major disease areas. Recently, re-
searchers are mainly focusing on developing new drugs from
marine cyanobacteria.22. Cyanobacteria
Studies of biomedical natural products have been concen-
trated only on Cyanophyta (blue-green algae) and Pyrrophyta
(dinoflagellates); most of the metabolites have been isolated
from cyanobacteria.3,4 Cyanobacteria have been considered a
rich source of secondary metabolites with potential biotech-
nological applications in the pharmacological field. Lately,
production of bioactive compounds with commercial and
medical applications has also increased interest in studying
these organisms.5 In fact, together with the production ofby Elsevier Taiwan LLC. All rights reserved.
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interesting in terms of their antifungal, antibiotic, and anti-
cancerigenous activities.6,7
Further, cyanobacterial metabolites show interesting and
exciting biological activities, including antimicrobial, immu-
nosuppressant, anticancer, anti-HIV (human immunodefi-
ciency virus), antibacterial, anticoagulant, antifungal, anti-
inflammatory, antimalarial, antiprotozoal, antituberculosis,
antiviral, and antitumor activities.8e10
The main emphasis is given on the search of drugs for
dreadful human diseases such as cancer and AIDS. In recent
years, scientists from different parts of the world have
discovered various drugs for the treatment of such diseases.
The chemical and biological diversity of the marine environ-
ment is immeasurable, making it an extraordinary resource for
the discovery of new anticancer drugs from cyanobacteria
(Table 1).15,22,24,25,47e101 This review highlights several ma-
rine natural products and their synthetic derivatives that are
currently undergoing clinical evaluation as anticancer drugs.11
The past decades have seen a dramatic increase in the number
of preclinical anticancer lead compounds obtained from
diverse marine species that have entered into human clinical
trials.12 Productivity in the past decades in terms of discovery
of new clinical anticancer leads from diverse marine life
should translate into a number of new treatments for cancer in
the years to come.
3. Cyanobacterial drugs for cancer
One of the most important treatments currently available
for cancer and other diseases is chemotherapy, which has
limited effectiveness due to some serious life-threatening side
effects and development of drug-resistant cancer cells. The
therapeutic efficacy and possible side effects vary among
different agents. Some drugs may have excellent efficacy but
can have very serious side effects. In addition, they may have
very limited supply and thus can be very expensive. However,
new drug discovery is a long and expensive process. It may
take as long as 15e20 years and as much as billions of dollars.
It is thus worthwhile to pursue a less expensive way for the
production of drugs that have been found to be effective, and
to develop a new way of administration or new delivery de-
vices to increase their efficacy and eliminate/decrease their
side effects. Side effects of anticancer drugs not only reduce
the efficacy of chemotherapy, but also compromise the quality
of Patient's life.13 The use of natural anticancer products, for
example, cyanobacterial anticancer metabolites, may improve
anticancer therapy.
Thus, cyanobacteria are promising but still unexplored nat-
ural resources offering a wealth of chemicals for the discovery
of lead compounds and new drugs. Of the new antibacterial and
anticancer drugs approved between 1983 and 1994, up to 80%
were derived from natural products. Traditional microbial drug
producers such as actinomycetes and hyphomycetes have been
the focus of pharmaceutical research for decades. Due to a
decrease in the rate of discovery of interesting compounds in
classical source organisms, it is time to turn to cyanobacteriaand exploit their potential. The biosynthetic information on the
chemical structures unique to these organisms will be very
valuable for finding out new anticancer agents.
4. Bioactive compounds from cyanobacteria
Cyanobacteria produce a wide variety of biomedically
interesting bioactive compounds, which are described below.4.1. BorophycinIt is obtained from Nostoc spongiaeforme var. tenue. It is a
boron-containing metabolite and has been found to have
effective cytotoxicity for human carcinoma.14e164.2. Borophycin-8It is obtained from Nostoc linckia.17 It is made up of two
identical halves with an overall structure reminiscent of other
boron-containing antibiotics. The C3 starter unit for the biosyn-
thesis of borophycin 8 is derived fromacetate andmethionine, but
not from propionate. Borophycin and four new cyclic hexapep-
tides containing no boron, tenuecyclamides AeD, were also
isolated from themethanol extract ofN. spongiaeformevar. tenue
collected from the Volcani Center, Israel.154.3. Apratoxin AIt is a cyanobacterial secondary metabolite, known as a
potent cytotoxic marine natural product. It is a derivative of
the apratoxin family of cytotoxins. The mixed pepti-
deepolyketide natural product comes from a polyketide syn-
thase/nonribosomal peptide synthase pathway. This cytotoxin
is known for inducing G1-phase cell cycle arrest and
apoptosis. This natural product's activity has made it a popular
target for the development of anticancer derivatives. Cyano-
bacterial metabolites are commonly found to be useful in
cancer treatment. In particular, apratoxin A has been found to
be a potent cancer cell cytotoxin. It has been found to be
remarkably cytotoxic in both in vitro and in vivo studies.
Although much work has been done to understand the mech-
anism of action of this cytotoxin, there is no definite under-
standing of how apratoxin A mediates antitumor activity in the
cell. In addition, apratoxin A lacks necessary selectivity to
become a potential antitumor agent, although numerous re-
ports have shown differential cytotoxicity in 60 tumor cell
lines.184.4. CryptophycinIt works by attacking the tubulin microfilaments found in
eukaryotic cells, thereby preventing cell division and repro-
duction. The main hypothesis as to why blue-green algae
produce this energetically expensive compound is that it is
used as a strong antifungal agent in order to prevent fungi or
other types of algae from competing with the cyanophyceae
for nutrients and sunlight. It has been found that the amount of
Table 1
Anticancer drugs from cyanobacteria.
S. no. Organisms Bioactive compounds Function Refs
1 Microcystis aeruginosa MicroviridinToxin BE-4,
siatoxin
Antibiotic, anticancer 47,48
2 Cyanobacteria N. linckia and
N. spongiaeforme var. tenue
Borophycin (image) Cytotoxicity against human epidermoid carcinoma (LoVo) and
human colorectal adenocarcinoma activity
15
3 Cyanobacteria Apratoxins Inhibition of a variety of cancer cell lines 25
4 Lyngbya majuscula Apratoxin A Cancer, U2OS osteosarcoma, HT29 colon adenocarcinoma, and
HeLa cervical carcinoma
25
5 Lyngbya sp. Apratoxins BeC KB oral epidermoid cancer and LoVo colon cancer 25
6 Lyngbya majuscula
and Lyngbya sordida
Apratoxin D H-460 lung cancer 49
7 Lyngbya bouillonii Apratoxin E U2OS osteosarcoma, HT29 colon adenocarcinoma, and HeLa
epithelial carcinoma
H-460 lung cancer
25
8 L. bouilloni Apratoxins F and G HCT-116 colorectal cancer cells 25
9 L. majuscula Aurilide B H-460 lung tumor 50
10 L. majuscula Aurilide C NCIeH460 lung tumor 50
11 Lyngbya bouillonii Alotamide 51
12 L. majuscula Antillatoxin 52
13 L. majuscula Antillatoxin B 53
14 L. bouillonii Bouillomides AeB 54,55
15 Symploca sp. Belamide A HCT-116 colon cancer 56
16 Lyngbya sp. Bisebromoamide HeLa S3 epithelial carcinoma 57
17 Lyngbya sp. Biselyngbyaside HeLa S3 epithelial carcinoma, SNB-78 central nervous system
cancer, and NCIe H522 lung cancer
24
18 Calothrix Calothrixin A HeLa epithelial carcinoma 58
19 Calothrix Calothrixin B HeLa epithelial carcinoma
Leukemia CEM
58
20 L. majuscula Caylobolide A HCT-116 colon tumor 22
21 Phormidium spp. Caylobolide B HT29 colorectal adenocarcinoma and HeLa cervical carcinoma 59
22 Leptolyngbya sp. Coibamide A Lung cancer NCIeH460, breast cancer MDA-MB-231, melanoma
LOX IMVI, leukemia HL-60 and astrocytoma SNB75, MDA-MB-
435 mammary adenocarcinoma, and SKOV3 ovarian carcinoma
60
23 N. linckia Cryptophycin-1 Cytotoxicity against human tumor cell lines and human solid
tumors
Leukemia U937, CCRF-CEM and HL-60, colon carcinoma HT-29,
GC3 and Caco-2, mammary carcinoma MCF-7 and MDA-MB-231,
and cervical carcinoma HeLa
61
24 N. spongiaeforme Cryptophycin-8 Greater therapeutic efficiency and lower toxicity than
cryptophycin-14 in vivo
62
25 Geitlerinema Ankaraholide A NCIeH460 lung tumor
MDA-MB-435 breast carcinoma, KB oral epidermoid cancer, and
LoVo colon cancer
63
26 Chondria sp.
Red algae
Condriamide A Cytotoxicity 64
27 Caulerpa sp.
Green algae
Caulerpenyne Cytotoxicity; anticancer, antitumor, and antiproliferative activities 65
28 Cystophora sp.
Brown algae
Meroterpenes and usneoidone Antitumor activity 66
29 Symploca sp.
(cyanobacterium)
Largazole Antiproliferative activity, cancer
MDA-MB-23I breast cancer and U2OS osteosarcoma
A549 lung cancer and HCT-116 colorectal carcinoma
25
30 L. bouilloni
(cyanobacterium)
Apratoxin A Cytotoxicity to adenocarcinoma 67
31 Leptolyngbya sp.
(cyanobacterium)
Coibamide A Cytotoxicity against NCIeH460 lung and mouse neuro-2a cells 66
32 Nostoc sp. GSV 224 Cryptophycin-1
Cryptophycin-52 (LY 355073)
Analog of cryptophycin-52
Adriamycin-resistant M 17 breast cancer and DMS 273 lung cancer
cell lines
68
33 L. majuscule
(cyanobacterium)
Curacin A Inhibits microtubule assembly 69
34 Symploca sp.
(cyanobacterium)
Dolastatin 10 Binds to tubulin on rhizoxin-binding site, and affects microtubule
assembly
70
(continued on next page)
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Table 1 (continued)
S. no. Organisms Bioactive compounds Function Refs
35 Symploca sp.
(cyanobacterium)
TZT-1027 analog of dolastatin 10 Effective against MX-1 breast carcinoma and LX-1 lung carcinoma
in both p53 normal and mutant cells
70
36 Leptolyngbya sp. Dolastatin 12 A549 lung carcinoma 71
37 Lyngbya sp. (cyanobacterium) Dolastatin 15 Breast cancers (binds directly to vinca alkaloid site of tubulin) 72
38 Lyngbya sp. (cyanobacterium) Cematodin
(LU-103793)
Analog of dolastatin 15
Breast cancers (binds directly to vinca alkaloid site of tubulin) 72
39 Lyngbya sp. ILX-651
(synthadotin)
Analog of dolastatin 15
Breast cancers (binds directly to vinca alkaloid site of tubulin) 72
40 Lyngbya sp. Apratoxin A Early-stage adenocarcinoma (induces G1-phase cell cycle arrest) 73
41 L. majuscula Dragonamide A-549 lung epithelial adenocarcinoma, HT-29 colon
adenocarcinoma, and MEL-28 melanoma
74
42 Oscillatoria margaritifera Ethyl tumonoate A H-460 lung cancer 75
43 Lyngbya confervoides Grassystatin AeB Lung cancer 76
44 L. majuscula Hectochlorin Lung cancer 77
45 L. majuscula Hermitamides AeB Lung cancer 78
46 Assemblage of L. majuscule
and Phormidium gracile
Hoiamide A H-460 lung cancer 79
47 Cyanobacterial sample Hoiamide B H-460 lung cancer 80
48 L. majuscula Homodolastatin 16 WHCO1 and WHCO6 esophageal cancer, and ME180 cervical
cancer
81
49 L. majuscula Isomalyngamide A and A-1 Breast cancer MCF-7 and MDA-MB-231 69
50 L. majuscula Jamaicamides AeC
nil
H-460 lung cancer 82
51 L. majuscula Kalkitoxin HCT-116 colon cancer 83
52 Lyngbya sp. Kempopeptin A Colon cancer 84
53 Lyngbya sp. Kempopeptin B Colon cancer 84
54 L. majuscula Lagunamide C Lung adenocarcinoma A549, cancer prostate PC3, ileocecal
colorectal cancer HCT8, and ovary cancer SK-OV
85
55 L. confervoides Largamides AeC Cancer 86
56 Oscillatoria sp. Largamides DeG Cancer 86
57 L. majuscula Lyngbyabellin A KB nasopharyngeal carcinoma and LoVo colon adenocarcinoma 70
58 L. majuscula Lyngbyabellin B Cancer 87
59 Lyngbya sp. Lyngbyaloside KB nasopharyngeal carcinoma and LoVo colon adenocarcinoma 70
60 L. majuscula Lyngbyastatin 1 Lung cancer 71
61 L. confervoides Lyngbyastatin 4 Lung cancer 87
62 Lyngbya spp. Lyngbyastatin 5e7 Lung cancer 79
63 Lyngbya semiplena Lyngbyastatin 8e10 Lung cancer 88
64 L. majuscula Majusculamide C Lung cancer NCIeH460, colorectal cancer KM20L2, and
glioblastoma SF-295
89
65 Symploca hydnoides Malevamide D Lung cancer A-549, colon cancer HT-29, and melanoma MEL-28 90
66 Symploca laete-viridis Malevamide E d 90
67 Dichothrix utahensis Molassamide d 90
68 L. sordida Malyngamide 2 H-460 lung cancer 45
69 L. majuscula Malyngamide C, J, and K H-460 lung cancer 91
70 L. majuscula Malyngolide dimmer H-460 lung cancer 91
71 Nostoc sp. Nostocyclopeptides A1 and A2 KB oral epidermoid cancer and LoVo colon cancer 92
72 L. confervoides Obyanamide KB oral epidermoid cancer and LoVo colon cancer 92
74 Lyngbya sp. Palauamide Cervical carcinoma HeLa, lung adenocarcinoma A549, and
gastrocarcinoma BGC
KB oral epidermoid cancer
92
75 L. majuscula Palmyramide A H-460 lung cancer 93
76 Assemblage of Leptolyngbya cf.
and Oscillatoria spp.
Palmyrolide H-460 lung cancer 93
77 L. majuscule Pitipeptolides AeB LoVo colon cancer 94,95
78 L. majuscule Pitipeptolide C HT29 colon adenocarcinoma and MCF-7 breast cancer 96
79 L. majuscule Pitiprolamide HCT116 colorectal carcinoma and MCF7 breast adenocarcinoma 97
80 L. confervoides Pompanopeptin A Carcinoma 86
81 L. majuscule Pseudodysidenin A-549 lung adenocarcinoma, HT-29 colon adenocarcinoma, and
MEL-28 melanoma
98
82 Symploca sp. Symplocamide H-460 lung cancer 84
83 S. hydnoides Symplostatin 1 MDA-MB-435 breast carcinoma and NCI/ADR ovarian carcinoma
Epidermoid carcinoma cell line
90
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Table 1 (continued )
S. no. Organisms Bioactive compounds Function Refs
84 Symploca sp. Symplostatin 3 Epidermoid carcinoma cell line 70
85 Symploca sp. Tasiamide KB oral epidermoid cancer and LoVo colon cancer 84
86 Symploca sp. Tasiamide B KB oral epidermoid cancer 99
87 Symploca sp. Tasipeptins AeB KB oral epidermoid cancer 84
88 L. confervoides Tiglicamides AeC
C-nil
Epidermoid cancer 86
89 Lyngbya sp. Ulongapeptin KB oral epidermoid cancer 99
90 S. cf. hydnoides Veraguamides AeG H-460 lung cancer 100
91 L. sordida Wewakazole H-460 lung cancer 101
92 L. semiplena Wewakpeptins H-460 lung cancer 100
93 L. majuscule
Schizothrix sp. assemblage
Somocystinamide A Cytotoxic against mouse neuro-2a neuroblastoma cells 46,101
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time depends on the current environmental conditions. The
recognizing property of cryptophycin allows it to recognize
cancerous tumor cells, even those of “solid tumors” such as
brain, colon, ovarian, prostate, pancreas, lung, and breast
cancers, and it can destroy the cells of multidrug-resistant
tumors. These are the cancers that chemotherapy has the
least ability to treat and account for 85% of all cancer deaths
in the United States.19 Cryptophycin is now being tested in
Phase I human clinical trials, and attempts have been made to
create synthetic cryptophycin analogs in the laboratory to be
used for further human clinical trials. Cryptophycin-1 obtained
from Nostoc sp. has potent cytotoxic activity against human
tumor cells, especially solid tumors.204.5. Cryptophycin-5It is a chemical analog of cryptophycin-1, which entered into
a clinical trial but produced only marginal activity.21 Two other
analogs, cryptophycins 249 and 309, with improved stability
and water solubility are being considered as second-generation
clinical candidates.22 The enhanced efficacy of these com-
pounds compared with that of cryptophycin-52 has prompted
new efforts to move these compounds into clinical trials.4.6. Cryptophycin-8In the studies reported, cryptophycin-8 was evaluated for
preclinical activity against subcutaneous tumors of both mouse
and human origins. Cryptophycin-8 was less potent than
cryptophycin-1 by approximately four-fold; however, it was
more water soluble and had greater therapeutic efficacy.23
Microalgae, notably Dunaliella and Spirulina, are also rich
sources of natural beta carotene (precursor of vitamin A) and
have been tested extensively for anticancer effects. Besides beta
carotene, a cyanophycean algal pigment, cryptophycin, has
demonstrated a powerful anticancer property that is especially
useful in the chemotherapy of drug-resistant tumors.4.7. StypoldioneIt is a marine natural product that possesses an antiquinone
functional group, which inhibits a variety of biologicalprocesses including cell division. Medina et al24 reported that
stypoldione binds covalently to sulfhydryl groups of thiol-
containing compounds via the addition of sulfur to the C-40
position of the quinone ring. They examined the ability of
stypoldione to add to sulfhydryl groups of a number of thiol-
containing substances, including glutathione, thiophenol, beta-
mercaptoethanol, and the protein tubulin.4.8. LargazoleLargazole, a cyclic depsipeptide obtained from a cyano-
bacterium of the genus Symploca, is a marine natural product
with a novel chemical scaffold and potently inhibits Class I
histone deacetylases (HDACs). It possesses highly differential
growth-inhibitory activity, preferentially targeting transformed
cells over nontransformed cells. The intriguing structure and
biological activity of largazole have attracted strong interest
from the synthetic chemistry community to establish synthetic
routes to largazole and to investigate its potential as a cancer
therapeutic. Hence, recent advances have a focus on the dis-
covery, synthesis, target identification, structureeactivity re-
lationships, HDAC8elargazole thiol crystal structure, and
biological studies, including in vivo anticancer and osteogenic
activities.254.9. Dolastatin 10It was originally isolated in a very low quantity from the
sea hare Dolabella auricularia, and it is actually a cyano-
bacterial metabolite, as confirmed by its direct isolation from a
Symploca sp.26 It is a pentapeptide containing four unique
amino acidsddolavaline, dolaisoleucine, dolaproline, and
dolaphenine. It is a potent antiproliferative agent. It binds to
tubulin on the rhizoxin-binding site and affects microtubule
assembly arresting the cell into G2/M phase. Unfortunately, in
clinical tests, its Phase II trial as a single agent was dis-
continued because of the development of peripheral neurop-
athy in 40% of patients and the lack of significant activity in
patients with hormone refractory metastatic adenocarcinoma27
and recurrent platinum-sensitive adenocarcinoma.28 An analog
of dolastatin 10, TZT-1027 (auristatin PE or soblidotin), which
differs from dolastatin 10 only in the absence of the thiazoline
ring from the dolaphenine residue, was found to be effective in
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LX-1 lung carcinoma in mice.29 It showed equivalent efficacy
against both p53 normal and mutant cell lines,30,31 demon-
strating that a conjugate of auristatin with a monoclonal
antibody directed to the adhesion molecule E-selectin can
inhibit the growth of prostate cancer cells.4.10. Dolastatin 15Another member of the dolastatin family, dolastatin 15, is a
linear peptide acting against various cancer cell lines. It binds
directly to the vinca alkaloid site on tubulin and blocks the
transition into M phase. No clinical trials have been under-
taken with this compound because of its structural complexity,
low synthetic yield, and poor water solubility. Cematodin (LU-
103793), a water-soluble analog of dolastatin 15, which has a
terminal benzylamine moiety in place of dolapyrolidone, re-
tains high cytotoxicity in vitro. It was found to be effective in a
Phase I trial for treatment of breast and other cancers by BASF
Pharma (Varanasi, India), but a Phase II trial was discontinued
following unexpected results. Currently, ILX-651 (synthado-
tin), a third-generation analog with a terminal tert-butyl moi-
ety in place of dolapyrolidone, has successfully passed Phase I
clinical trial, and a Phase II trial has been recommended.324.11. Calothrixin ACell extracts of Calothrix isolates were found to be helpful
in inhibiting the growth of human HeLa cancer cells in a dose-
dependent manner. Calothrixin A and B, pentacyclic metab-
olites, are obtained from microalgae, which have growth
inhibitory effects. More than 50% of the marine cyanobacteria
are potentially exploitable for extracting bioactive substances
that are effective in either killing the cancer cells by inducing
apoptotic death or affecting the cell signaling through activa-
tion of the members of protein kinase-c family of signaling
enzymes. Cell extracts of Calothrix isolates inhibit the growth
in vitro of a chloroquine-resistant strain of the malarial para-
site Plasmodium falciparum and of human HeLa cancer cells
in a dose-dependent manner. Bioassay-directed fractions of the
extracts have led to their isolation and structural character-
ization of calothrixin A and B, pentacyclic metabolites with
indole phenanthridine alkaloids, which exert their growth
inhibitory effects at nanomolar concentrations.334.12. Symplocin ASymplocin A is a new N,N-dimethyl-terminated peptide
extracted from the Bahamian cyanobacterium Symploca sp.
The complete absolute configuration of symplocin A,
including the unexpected D configurations of the terminal
N,N-dimethylisoleucine and valic acid residues, was assigned
by chiral-phase high-performance liquid chromatography of
the corresponding 2-naphthacyl esters, a highly sensitive,
complementary strategy for assignment of N-blocked peptide
residues where Marfey's method is ineffectual or othermethods fall short. Symplocin A exhibits potent activity as an
inhibitor of cathepsin E.344.13. Lyngbyatoxin ALyngbyatoxin A and debromoaplysiatoxin are two highly
inflammatory but structurally different metabolites isolated
from the toxic strains of Lyngbya majuscula collected from
Hawaii,35 and anatoxin-a from Anabaena ciecinalis.36 Some
anti-HIV activities have been observed with the compounds
extracted from Lyngbya lagerhaimanii and Phormidium
tenue.37,384.14. Microcolin AAn immunosuppressive linear peptide microcolin A,
at nanomolar concentrations, suppresses the two-way murine-
mixed lymphocyte reaction. It was isolated from L.
majusculata.394.15. Curacin AA unique thiozoline-containing compound, curacin A, has
been purified from the organic extract of a Curacao collection
of L. majusculata.40 This compound has been found to have
potential activity against breast cancer.414.16. Cyanobacterial drugs for AIDSThe global spread of deadly viral diseases such as HIV-
acquired immune deficiency syndrome and dengue may have
dramatic consequences. New potent and safe antiviral agents
are urgently needed in this situation. Presently, the only
approved anti-HIV treatment (highly active antiretroviral tri-
therapy), which is effective in controlling the progression of
HIV infections, has been proved to be toxic, to induce strong
viral resistance, and to be unable to eradicate the causative
viral agent.42 The following are the three classes of cyano-
bacterial compounds with potent in vitro antiviral activity. The
most significant antiviral cancer polysaccharides are spirulan
and Ca-spirulan from Spirulina sp. These compounds showed
potent and broad-spectrum activity against HIV-1, HIV-2, H,
influenza, and a series of other enveloped viruses. They inhibit
the reverse transcriptase activity of HIV-1 (like azidothymi-
dine). These sulfated polysaccharides prevent virusecell
attachment and fusion with host cells. They also inhibit the
fusion between HIV-infected and HIV-uninfected CD4þ
lymphocytes, a mechanism that greatly enhances viral infec-
tivity. These compounds have advantages as antiviral agents
over other sulfated polysaccharides because of reduced anti-
coagulant properties.43 Nostoflan, an acidic polysaccharide
from Nostoc flagelliforme that exhibits potent virucidal ac-
tivity against herpes simplex virus-1, is also noteworthy.
Currently, two carbohydrate-binding proteins, namely,
cyanovirin-N and scytovirin, are being developed as potent
virucidal drugs. These carbohydrate-binding proteins show
21S. Vijayakumar, M. Menakha / Journal of Acute Medicine 5 (2015) 15e23antiviral activity by interfering with multiple steps in the viral
fusion process.4.17. Cyanovirin-NIt is a 101-amino-acid-long, 11 kDa polypeptide isolated
from Nostoc ellipsosporum, showing potent in vitro and in vivo
activities against HIV and other lentiviruses in nanomolar
concentrations. It interferes with the binding of HIV gp120
proteins with CD4þ receptors and the chemokine CCR5 or
CXCR4 coreceptors of target cells, and, thus, inhibits fusion of
HIV virus with CD4 cell membrane. It also inhibits herpes
simplex virus-6 and measles virus in vitro.4.18. ScytovirinIt is a 95-amino-acid-long, 9.7 kDa polypeptide containing
five intrachain disulfide bonds. It was first isolated from the
aqueous extract of Scytonema varium. It binds to the envelope
glycoprotein of HIV (gp120, gp160, and gp41) and inactivates
the virus in low nanomolar concentrations. A nuclear magnetic
resonance analysis has revealed that scytovirin has two do-
mains and the first domain (1e48 amino acids) has similar
anti-HIV activity to that of the full-length scytovirin.44 In
addition, two cyclic depsipeptides, ichthyopeptins A and B,
were also isolated from Microcystis ichthyoblabe. They have
shown antiviral activity against influenza A virus.
5. Conclusion
Cyanobacteria constitute a unique group of oxygenic
photosynthetic bacteria and populate diverse habitats
throughout the world. Their potential as a good source of new
therapeutic lead compounds has been realized during the past
two decades, as several bioactive molecules obtained from
cyanobacteria show a broad spectrum of activities, such as
antitumor, antibacterial, and antiviral effects, and protease in-
hibition. Another advantage of cyanobacteria as a microbial
source for drug discovery lies in the economy of their cultivation
comparedwith othermicroorganisms, as the former require only
simple inorganic nutrients for growth. Thus, it seems that the
cyanobacteria have the potential for expanded utilization in drug
discovery. Further, owing to a high degree ofmicrobial diversity,
cyanobacterial secondary metabolites may constitute a prolific
source of new entities leading to the development of new
pharmaceuticals.45 Yet, exploitation of the cyanophycean spe-
cies has been hampered by a number of issues related to their
handling. With most of these problems having been resolved
now, cyanobacteria have the potential to expand the variety of
natural products obtained from microorganisms. The relative
disregard of cyanobacteria in the past compared with other
microbial sources of natural products, as well as the huge
chemical diversity and biological activities of their products, has
made them attractive sources of novel drugs for use in diverse
therapeutic areas.46 Hence, pharmaceutical potential of cyano-
bacteria deserves more scientific attention and interdisciplinaryresearch, and cyanobacterial strains from still unexplored and
extreme habitats can serve as good candidates in this regard.
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